Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
DROPsept
- Development stage
- Unknown
- Lead developer
- SERVImed Industrial
- Modality
- Small Molecules
- Administration
- Ophthalmic, Topical
01
Overview
**DROPsept** is a CE-marked Class IIB ophthalmic medical-device eye-drop product developed by Iromed. It is a multidose topical ophthalmic solution containing chlorhexidine digluconate and vitamin E TPGS, formulated to enhance chlorhexidine availability in corneal tissue. The product is used as an adjunct to protect and support repair of corneal and conjunctival epithelium and for symptoms associated with ocular-surface inflammation, including conjunctivitis, keratitis, blepharitis, dacryocystitis, meibomitis, and dry eye syndrome. It is also positioned for presurgical and postsurgical ocular-infection prophylaxis and is compatible with contact lenses.
- Brand names
- DROP septDROPsept
Beyond the preview
Go deeper on DROPsept.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on DROPsept.